Search

Displaying results 3491 - 3500 of 10000 in total
  1. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

  2. Drug

    Hypochlorite

    go.drugbank.com/drugs/DB11123
    ApprovedInvestigational

    Hypochlorite is an ion composed of chlorine and oxygen with the chemical formula ClO−. … Being unstable in the pure form, hypochlorite is most commonly used for bleaching, disinfectation, and water treatment purposes in its salt form, sodium hypochlorite.

    Products: NaOClean E-Water
  3. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

  4. Target

    Nectin-4

    go.drugbank.com/bio_entities/BE0009798
    TargetHumans

    Does not act as receptor for alpha-herpesvirus entry into cells

    Synonyms: Ig superfamily receptor LNIR, Poliovirus receptor-related protein 4
  5. Target

    NKG2-A/NKG2-B type II integral membrane protein

    go.drugbank.com/bio_entities/BE0010560
    TargetHumans

    Immune inhibitory receptor involved in self-nonself discrimination. … Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions (PubMed:30860984, PubMed:9430220, PubMed:9485206, PubMed:9486650).

    Synonyms: NK cell receptor A, NKG2-A/B-activating NK receptorFunction: HLA-E specific inhibitory MHC class Ib receptor activity
  6. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    [A254736,A254741] Olutasidenib is orally bioavailable and capable of penetrating the blood-brain barrier, and is also being evaluated for the treatment of myelodysplastic syndrome (MDS), as well as solid … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.

  7. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.

    Categories: GABA-A Receptor Agonists, gamma-Aminobutyric Acid A Receptor Agonist
  8. Drug

    Argatroban

    go.drugbank.com/drugs/DB00278
    ApprovedInvestigational

    Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. … Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi.

  9. Drug

    Sulfamethazine

    go.drugbank.com/drugs/DB01582
    ApprovedVet approvedWithdrawn

    It has a spectrum of antimicrobial action similar to other sulfonamides.

  10. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860] … Niclosamide is an antihelminthic used for the treatment of tapeworm infections.